Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Intraoperative cell salvage reduces the number of patients
needing allogenic blood or blood products during coronary artery bypass
surgery. In McGill and colleagues' randomised controlled trial of 252 patients having elective coronary bypass surgery (p 1299), 31% of
patients in whom intraoperative cell salvage was used required a blood
transfusion, compared with 51% of patients in whom no form of
mechanical blood conservation was used. Reducing the amount of blood
transfused during surgery benefits patients by lowering their risk of
contracting bloodborne or other infections or having a perioperative
myocardial infarction.